Objective. Blindness is a recognized complication of GCA; however, the frequency of and risk factors for this complication have not been firmly established. The aim of this study was to examine the incidence and determinants of blindness in patients with GCA, using a large international cohort.
Introduction
GCA is the commonest form of large vessel vasculitis, with an estimated annual incidence of up to 32.8/ 100 000 individuals >50 years old [1] . Blindness is a well-recognized complication of GCA; however, information to date on the occurrence of visual loss in GCA is inconsistent and difficult to interpret. Previous studies have been conducted in small, selected, hospital-based patient series using different definitions of disease and clinical outcome, and have resulted in imprecise estimates of risk, ranging from 2.9 to 66.2% [2, 3] . Registry-based surveys have involved larger sample sizes but include less precise clinical detail.
Prompt treatment of patients with GCA with glucocorticoids may prevent visual loss but rarely reverses established changes [4] , and better understanding is needed of the factors which place subjects at particular risk at the time they first present. Studies have implicated pre-existing vascular disease as a potential risk factor for subsequent visual loss in GCA [59] . However, considerable uncertainty remains because no single vascular risk factor has been reported consistently.
In this analysis we examine the rate of visual loss in the Diagnostic and Classification Criteria in Vasculitis Study (DCVAS), a large international cohort of well-characterized patients with GCA [10] . We examine the potential risk factors for blindness and focus on the association of vascular disease with ophthalmologic outcomes in GCA. Case ascertainment-GCA definition As part of the DCVAS protocol, the examining physician was required to submit an assessment of their level of diagnostic certainty (very certain, 575%; moderately certain, 5074%; uncertain, 2549%; very uncertain, <25%) for each participant. Musculoskeletal features were also recorded, but not whether patients had a prior diagnosis of PMR. Patients were included in the present analysis if they had a new baseline diagnosis of GCA (i.e. not relapsing disease) that was confirmed after 6 months with a confidence level of 575%. Also available were the results of temporal artery biopsy (TAB) to allow patients to be classified using the 1990 ACR criteria set for GCA [11] . A positive TAB was defined as the presence of inflammatory cell infiltrate and/or presence of giant cells.
Patients and methods

Setting
Definition of blindness
The occurrence of new-onset blindness at 6 months was assessed using the Vasculitis Damage Index (VDI) [12] , which defines blindness in one or both eyes as complete loss of vision. Also recorded at baseline were data on ophthalmic features: amaurosis fugax (transient monocular blindness), sudden ongoing visual loss (loss of vision, either a visual field defect or blindness), blurred vision or diplopia (double vision). The VDI also records diplopia and visual impairment as a single item. This was not included as a primary outcome measures due to the lack of consistency in definition.
Previous medical history
The DCVAS protocol records for all patients the previous history of medical conditions present before the onset of the current illness. Conditions specifically documented include: coronary heart disease, heart failure, peripheral vascular disease (PVD), hypertension requiring medication, chronic obstructive pulmonary disease, asthma, diabetes mellitus, cerebrovascular accident (CVA), dyslipidaemia and malignancy. These diagnoses were defined as, in common with many large registry datasets, a physician-recorded entry in the patients' care record.
Statistical approach
Descriptive statistics were used to assess patient characteristics, with standard non-parametric tests used to assess differences between groups. Previous publications have found an association between laboratory markers and subsequent blindness, including relatively lower inflammatory markers, anaemia and thrombocytosis [5, 6, 13] . For these reasons, inflammatory markers (ESR and CRP) and haematological tests (anaemia-haemoglobin (Hb) <100 g/l and platelets >500 Â 10 9 /l) were assessed for their association with subsequent blindness. Previous data suggested a relationship between prior vascular disease and ischaemic complications in GCA. A logistic regression analysis was applied to examine the strength of the association between vascular risk factors and blindness at 6 months, recorded as odds ratios (ORs) with 95% CIs. In a sensitivity analysis, the models were recalculated, first using the 1990 ACR criteria set and second using positive temporal artery biopsy findings to define GCA diagnosis. Statistical analysis was carried out using STATA version 12 (StataCorp LP, TX, USA).
Results
Of the 715 patients recruited into DCVAS by 30 December 2014 with complete data, 433 were considered to have GCA with 575% diagnostic certainty at 6 months; 404 fulfilled the 1990 ACR criteria for GCA; and 235 had a positive TAB. The patients were in the main (95.6%) Caucasians from Europe or North America (baseline characteristics- Table 1 ). Six months after diagnosis, 34 patients (7.9%) had monocular blindness, of whom 3 (0.7%) had binocular blindness (with no statistically significant difference in the rate of blindness between men and women).
Thirty-one of the patients who had blindness recorded at 6 months (22 women and 12 men) had presented with symptoms of sudden visual loss, with only two patients not having visual disturbance (including amaurosis fugax, visual loss, blurred vision or diplopia) at baseline being declared blind at 6 months. The visual manifestations of disease for all patients with GCA at presentation included: blurred vision in 98 (22.6%), sudden visual loss in 70 (16.2%), diplopia in 51 (11.8%), amaurosis fugax in 33 (7.6%) and red eyes in 9 (2.1%). As expected, blindness at 6 months occurred more frequently in those who presented with visual symptoms. Of those with sudden visual loss at presentation, 44.3% (31/70) were blind at 6 months as assessed on the VDI; of those with no recorded visual loss at presentation, 0.8% (3/363) were recorded as being blind at the 6 month review. Patients who developed blindness had a lower CRP at presentation; however, no other clinical feature of GCA itself was associated significantly with blindness at 6 months.
www.rheumatology.oxfordjournals.org Table 2 shows the results of logistic regression analysis examining associations between potential vascular risk factors assessed at baseline and blindness (adjusted for age and sex). Factors positively associated with blindness at 6 months included a prior history of CVA (OR = 4.47, 95% CI: 1.30, 15.41) and PVD (OR = 10.44, 95% CI: 2.9437.03). There was no association between baseline laboratory findings and blindness.
In the sensitivity analysis, the findings were largely unchanged. The rates of blindness in those meeting the 1990 ACR criteria and those with a positive TAB were 7.4 and 9.8%, respectively. The associations between PVD and CVA remained statistically significant, with positive associations for blindness at 6 months [for PVD, ACR cases OR = 9.40 (95% CI: 2.14, 41.34), TAB-positive cases OR = 9.22 (95% CI: 
Discussion
This large observational study demonstrates that blindness remains a major problem in GCA. Around 1 in 12 patients was blind in 1 eye by 6 months after diagnosis. Most patients who developed blindness did so by the time of their first assessment, with only two patients without symptoms of visual disturbance suffering blindness at 6 months. These results re-emphasize the need for urgent referral and rapid institution of glucocorticoid therapy [14] . Our analysis shows an association between blindness and PVD.
The rate of blindness identified in the present study is lower than the majority of published estimates, possibly, reflecting our narrower and more stringent definition of blindness. It could be that more patients suffered visual loss, since 70 patients were noted to have this complication at their baseline visit. However, data from the Mayo clinic (which published data on 204 cases of GCA from Rochester, Minnesota, USA over a 55-year period) revealed that 47 patients (23.0%) had visual symptoms, with 7 (3.4%) suffering blindness in at least one eye (of whom 2 had bilateral blindness), which is lower than our estimate [15] . Subsequently this same research group reported that 8.2% of patients with GCA had permanent visual loss attributed to their vasculitis; these newer data are more consistent with our current estimate [16] . Our estimate is higher than the 2.9% reported in the register-based study conducted by Mollan et al. [2] , interpretation of which is limited both by the fact that the cases were identified though hospital episodes, and that classification criteria were not applied, potentially leading to an underestimate of the rate of blindness in those with GCA. In addition, care episodes (rather than individual patient records) were used, leading to the potential for double or multiple counting. Values given as n (%) unless otherwise indicated.
a P-value of difference between those who were subsequently declared blind in at least one eye versus those who were not; all calculated using the Chi-squared test except for median age at diagnosis, ESR and CRP, which were tested by the MannWhitney test. IQR: interquartile range.
In keeping with other studies, a lower mean inflammatory marker result was noted in those with blindness, which reached statistical significance for CRP but not for ESR. It may be that patients with lower inflammatory markers at baseline assessment are at greater risk of blindness due to prior inadequate treatment with glucocorticoids; equally, it may be a factor that contributes to diagnostic delay, or reflect a propensity for inflammation in smaller vessels. We also identified prior PVD as a risk factor for blindness in patients with GCA. Previous studies have implicated hypertension, a past history of ischaemic heart disease, thrombocytosis, constitutional symptoms and low inflammatory response as potential risks for blindness [5, 6, 17] . While reports have been inconsistent and many of these factors were not confirmed in the present study, taken together these findings suggest a potential role of endothelial dysfunction in both the development of GCA and its ischaemic complications. The increased risk of CVD following a diagnosis of GCA is also consistent with this hypothesis [18] .
A strength of this study is its size: 433 new cases of GCA were included, each of which had a systematic structured assessment that included presenting features, comorbidities and outcome at 6 months. Outcomes were assessed by the VDI, a validated means of recording permanent damage arising from vasculitis or its treatment.
Limitations of the study include referral bias due to the fact that it was clinic-, rather than population-based. However, our sample was not selected from an individual specialty or specialist centre, providing potentially greater generalizability than prior single-centre studies. A formal ophthalmological assessment was not carried out routinely as part of DCVAS, and the study protocol does not include additional review of the care records. Other limitations include the descriptions used for visual change and loss recorded within the DCVAS case report form, which we were concerned may not have been uniformly applied. We therefore chose to use the most definitive outcome measure available, that is, complete loss of vision in the affected eye.
It is difficult to comment in full on the detailed causal pathways involved in those whose symptoms evolved over the 6 months of follow-up, but we note that only two patients without any visual disturbance were declared blind in one eye at 6 months. Our analysis of obesity and blindness needs to be treated with caution due to the relatively high proportion of missing values for BMI in this dataset. We do not have information regarding the initial dose, route or timing of glucocorticoid therapy or anti-platelets such as aspirin. We do note, however, that recent database studies in GCA [18, 19] have not included glucocorticoid treatment as a separate covariate, because their use is advised as the standard management for GCA [20] , and it was therefore not considered possible to separate the effect of treatment and disease. This is the largest study to date of visual loss in cases of clinically confirmed GCA and provides a robust estimate of blindness associated with a diagnosis of GCA. Blindness, both monocular and binocular, remains a major problem in GCA, and this study points to the need to be especially vigilant of this outcome in patients with a higher conventional vascular risk. with M.Y.; J.R. commented on drafts of the manuscript; A.C. is the research co-ordinator for the DCVAS study and carried out database searches and produced the dataset; P.A.M., R.A.L. and R.A.W. and the main investigators for the DCVAS study have been involved in the design, setup, ethical approval, recruitment of the DCVAS study, and are custodians of the data; co-authors have all commented on the manuscript drafts. 
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